

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 18, 2025

Mcl-1

RRID:AB_2722740

Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 94296, RRID:AB_2722740)

Antibody Information

URL: http://antibodyregistry.org/AB_2722740

Proper Citation: (Cell Signaling Technology Cat# 94296, RRID:AB_2722740)

Target Antigen: Mcl-1

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IF-IC, F

Antibody Name: Mcl-1

Description: This monoclonal targets Mcl-1

Target Organism: rat, mouse, human

Clone ID: D2W9E

Antibody ID: AB_2722740

Vendor: Cell Signaling Technology

Catalog Number: 94296

Alternative Catalog Numbers: 94296S

Record Creation Time: 20231110T033720+0000

Record Last Update: 20240725T100603+0000

Ratings and Alerts

No rating or validation information has been found for Mcl-1.

No alerts have been found for Mcl-1.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Wright T, et al. (2024) Anti-apoptotic MCL-1 promotes long-chain fatty acid oxidation through interaction with ACSL1. *Molecular cell*.

Perkins DW, et al. (2024) Therapy-induced normal tissue damage promotes breast cancer metastasis. *iScience*, 27(1), 108503.

Simoni-Nieves A, et al. (2024) A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib. *Cell reports. Medicine*, 5(9), 101703.

Perurena N, et al. (2023) USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. *Cell reports. Medicine*, 4(4), 101007.

Malvi P, et al. (2023) HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B. *Cell reports. Medicine*, 4(11), 101285.

Jia P, et al. (2023) CCDC50 promotes tumor growth through regulation of lysosome homeostasis. *EMBO reports*, 24(10), e56948.

Liedmann S, et al. (2022) Localization of a TORC1-eIF4F translation complex during CD8+ T cell activation drives divergent cell fate. *Molecular cell*, 82(13), 2401.

Pesch AM, et al. (2022) Bcl-xL inhibition radiosensitizes PIK3CA/PTEN wild-type triple negative breast cancers with low Mcl-1 expression. *Cancer research communications*, 2(7), 679.

Shimizu K, et al. (2021) Interplay between protein acetylation and ubiquitination controls MCL1 protein stability. *Cell reports*, 37(6), 109988.

Sheppard HE, et al. (2021) Targeted brachyury degradation disrupts a highly specific

autoregulatory program controlling chordoma cell identity. Cell reports. Medicine, 2(1), 100188.

Ho JJD, et al. (2021) Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome. Cell reports, 37(2), 109806.

Inde Z, et al. (2020) Kinetic Heterogeneity of Cancer Cell Fractional Killing. Cell reports, 32(1), 107845.

Jin S, et al. (2020) 5-Azacididine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(13), 3371.

Petsri K, et al. (2020) Structure-Activity Relationships and Molecular Docking Analysis of Mcl-1 Targeting Renieramycin T Analogues in Patient-derived Lung Cancer Cells. Cancers, 12(4).

Bhatt S, et al. (2020) Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer cell, 38(6), 872.

LeBlanc L, et al. (2018) Yap1 safeguards mouse embryonic stem cells from excessive apoptosis during differentiation. eLife, 7.